Patent ID: 11883383
Assignee: VTV THERAPEUTICS LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 0:
1. A crystalline form of a saccharinate, vanillate, fumarate, galactarate, hippurate, L-malate, oxalate, or mesylate salt of [3-(4-{2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-propyl]-diethylamine, wherein: the pharmaceutically acceptable acid is selected from the group consisting of
a) the crystalline form of the saccharinate salt is characterized by at least two of the following features (I-i)-(I-iv):
(I-i) an X-ray Powder Diffraction (XRPD) pattern having peaks at 2θ angles of 18.1, 21.1, and 25.7°±0.2°;
(I-ii) a Differential Scanning Calorimetry (DSC) profile as shown in FIG. 3;
(I-iii) a TGA profile as shown in FIG. 3; or
(I-iv) a 13C Solid-state Nuclear Magnetic Resonance (SSNMR) spectrum as shown in FIG. 53;

b) the crystalline form of the vanillate salt is characterized by at least two of the following features (I-i)-(I-iv):
(I-i) an XRPD pattern having peaks at 2θ angles of 7.6°, 15.2°, and 18.2°±0.2°;
(I-ii) a DSC profile as shown in FIG. 6;
(I-iii) a TGA profile as shown in FIG. 6; or
(I-iv) a 13C SSNMR spectrum as shown in FIG. 54;

c) the crystalline form of the fumarate salt is characterized by at least two of the following features (I-i)-(I-iv):
(I-i) an XRPD pattern having peaks at 2θ angles of 16.6°, 18.0°, and 21.5°±0.2°;
(I-ii) a DSC profile as shown in FIG. 13;
(I-iii) a TGA profile as shown in FIG. 13; or
(I-iv) a 13C SSNMR spectrum as shown in FIG. 57;

d) the crystalline form of the galactarate salt is characterized by at least two of the following features (I-i)-(I-iv):
(I-i) an XRPD pattern having peaks at 2θ angles of 8.0°, 14.6°, and 19.7°±0.2°;
(I-ii) a DSC profile as shown in FIG. 19;
(I-iii) a TGA profile as shown in FIG. 19; or
(I-iv) a 13C SSNMR spectrum as shown in FIG. 59;

e) the crystalline form of the hippurate salt is characterized by at least two of the following features (I-i)-(I-iv):
(I-i) an XRPD pattern having peaks at 2θ angles of 3.4°, 20.2°, and 20.9°±0.2°;
(I-ii) a DSC profile as shown in FIG. 29;
(I-iii) a TGA profile as shown in FIG. 29; or
(I-iv) a 13C SSNMR spectrum as shown in FIG. 62;

f) the crystalline form of the L-malate salt is characterized by at least two of the following features (I-i)-(I-iv):
(I-i) an XRPD pattern having peaks at 2θ angles of 3.7°, 17.2°, and 19.0°±0.2°;
(I-ii) a DSC profile as shown in FIG. 32;
(I-iii) a TGA profile as shown in FIG. 32; or
(I-iv) a 13C SSNMR spectrum as shown in FIG. 63;

g) the crystalline form of the oxalate salt is characterized by at least two of the following features (I-i)-(I-iv):
(I-i) an XRPD pattern having peaks at 2θ angles of 16.1°, 17.8°, and 21.9°±0.2°;
(I-ii) a DSC profile as shown in FIG. 34;
(I-iii) a TGA profile as shown in FIG. 34; or
(I-iv) a 13C SSNMR spectrum as shown in FIG. 64;

h) the crystalline form of the mesylate salt is characterized by at least two of the following features (I-i)-(I-iv):
(I-i) an XRPD pattern having peaks at 2θ angles of 20.3°, 22.4°, and 23.5°±0.2°;
(I-ii) a DSC profile as shown in FIG. 43;
(I-iii) a TGA profile as shown in FIG. 43; or
(I-iv) a 13C SSNMR spectrum as shown in FIG. 66.